A phase Ib/IIa, randomised, double blind, parallel group, placebo controlled, multicentre study to assess the safety and efficacy of expanded Cx611 allogeneic adipose-derived stem cells (eASCs) for the intravenous treatment of adult patients with severe community-acquired bacterial pneumonia and admitted to the intensive care unit

Trial Profile

A phase Ib/IIa, randomised, double blind, parallel group, placebo controlled, multicentre study to assess the safety and efficacy of expanded Cx611 allogeneic adipose-derived stem cells (eASCs) for the intravenous treatment of adult patients with severe community-acquired bacterial pneumonia and admitted to the intensive care unit

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 14 Aug 2017

At a glance

  • Drugs Cx 611 (Primary)
  • Indications Sepsis
  • Focus Adverse reactions
  • Acronyms SEPCELL
  • Sponsors TiGenix
  • Most Recent Events

    • 12 Aug 2017 This trial has been suspended in Spain.
    • 06 Apr 2017 According to a TiGenix media release, data from this trial are expected in 2019.
    • 31 Jan 2017 Status changed from planning to recruiting according to a TiGenix media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top